Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lundbeck Defends Its Escitalopram Patent In Denmark, But Not In Spain

This article was originally published in The Pink Sheet Daily

Executive Summary

Lundbeck's top-selling product, Cipralex, is responsible for more than half its sales, but faces generic competition in Spain.

You may also be interested in...



Lundbeck’s New Partners: Research With Genmab, Marketing With Merck

Lundbeck has entered into a research collaboration with fellow Danish company Genmab, its first since announcing a new R&D strategy in September. It’s the second collaboration for Genmab since that company also updated its corporate strategy at around the same time.

Lundbeck’s New Partners: Research With Genmab, Marketing With Merck

Lundbeck has entered into a research collaboration with fellow Danish company Genmab, its first since announcing a new R&D strategy in September. It’s the second collaboration for Genmab since that company also updated its corporate strategy at around the same time.

Lundbeck's New Partnering Focus: Link Up With Genmab On Research And Merck On Marketing Sycrest

Lundbeck to collaborate on CNS research with fellow Danish firm Genmab, and to exclusively market Merck's antipsychotic Sycrest outside the U.S., China and Japan.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel